Breaking News

Monoclonal Antibody Cocktail Significantly Reduced Symptomatic COVID-19

January 14, 2022 • 3:03 pm CST
(Precision Vaccinations)

The JAMA Network published the results of a randomized clinical study on January 14, 2022, reporting treatment with subcutaneous casirivimab and imdevimab (REGEN-COV) monoclonal antibody (mAbs) compared with placebo significantly reduced the incidence of symptomatic COVID-19 among recently exposed, asymptomatic individuals.

This difference was statistically significant.

This phase 3 study found intravenous infusion of REGEN-COV, compared with placebo, led to an approximately 70% relative reduction in hospitalization and all-cause mortality, with absolute rates of 1% vs. 3.2% in the 1200-mg treatment and placebo groups, respectively.

In this study at 112 sites in the United States, Romania, and Moldova that included 314 SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living with an infected household contact, 29% of asymptomatic seronegative participants treated with subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each antibody), developed symptomatic COVID-19 over 28 days vs. 42.3% of those treated with placebo.

In a related Editorial published by the JAMA Network, Jonathan Z. Li, M.D., and Rajesh T. Gandhi, M.D. wrote 'Those with mild or moderate COVID-19 often have high nasopharyngeal SARS-CoV-2 levels, and it is in this phase that antiviral therapy, such as anti–SARS-CoV-2 monoclonal antibodies, appears to be most beneficial.'

'Monoclonal antibodies are currently used for postexposure prophylaxis and treatment of symptomatic SARS-CoV-2 infection.'

'Extraordinary progress has occurred in expanding the role of anti–SARS-CoV-2 mAbs for COVID-19, but several remaining questions must still be addressed, such as does treatment ameliorate post-acute sequelae of SARS-CoV-2?

As of January 14, 2022, the U.S. NIH's OpenData Portal reported REGEN-COV in vitro Therapeutic Activity. But, given the breaking nature of these releases, Omicron data should be interpreted with caution.

Previously, Regeneron Inc. announced on December 16, 2021, while REGEN-COV antibodies have diminished potency against Omicron, they are active against the Delta variant.